The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

As CEOs continue to digest the fallout of the murder of UnitedHealthcare CEO Brian Johnson, a billionaire backer of major ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Shares of AstraZeneca PLC AZN inched up 0.25% to £105.38 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.26% to 8,301.62.

AstraZeneca PLC ADR closed $20.28 below its 52-week high ($87.68), which the company achieved on August 30th.

As the current system falters under the weight of inefficient processes and systemic barriers, this is not just a matter of ...